BACKGROUND Data on optimal antiplatelet treatment regimens in patients who undergo multivessel percutaneous coronary intervention (PCI) are sparse. OBJECTIVES This post hoc study investigated the impact of an experimental strategy (1-month dual antiplatelet therapy [DAPT] followed by 23-month ticagrelor monotherapy) versus a reference regimen (12-month DAPT followed by 12-month aspirin monotherapy) according to multivessel PCI. METHODS The GLOBAL LEADERS trial is a prospective, multicenter, open-label, randomized controlled trial, allocating all-comer patients in a 1:1 ratio to either the experimental strategy or the reference regimen. The primary endpoint was the composite of all-cause death or new Q-wave myocardial infarcti...
Background: Dual antiplatelet therapy (DAPT) with a potent P2Y12 Inhibitor coupled with aspirin for ...
Patients undergoing staged percutaneous coronary intervention (SPCI) are exposed to extended duratio...
Background: The optimal antiplatelet strategy in the second year after percutaneous coronary interve...
BACKGROUND The GLOBAL LEADERS (GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-plate...
OBJECTIVES The aim of this study was to compare ticagrelor monotherapy with dual-antiplatelet the...
AIMS To evaluate the impact of an experimental strategy [23-month ticagrelor monotherapy followi...
(1) Shorter-duration dual antiplatelet therapy (DAPT) followed by single antiplatelet therapy has be...
Objectives: The aim of this study was to compare ticagrelor monotherapy with dual-antiplatelet thera...
Background: The GLOBAL LEADERS (GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platele...
Aims: To evaluate the impact of an experimental strategy [23-month ticagrelor monotherapy following ...
Aims: Optimal timing and strategy of antiplatelet monotherapy after dual-antiplatelet therapy (DAPT)...
BACKGROUND The optimal antiplatelet strategy in the second year after percutaneous coronary inter...
BACKGROUND We hypothesised that ticagrelor, in combination with aspirin for 1 month, followed by tic...
Patients undergoing staged percutaneous coronary intervention (SPCI) are exposed to extended duratio...
BACKGROUND: In TWILIGHT (Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Inter...
Background: Dual antiplatelet therapy (DAPT) with a potent P2Y12 Inhibitor coupled with aspirin for ...
Patients undergoing staged percutaneous coronary intervention (SPCI) are exposed to extended duratio...
Background: The optimal antiplatelet strategy in the second year after percutaneous coronary interve...
BACKGROUND The GLOBAL LEADERS (GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-plate...
OBJECTIVES The aim of this study was to compare ticagrelor monotherapy with dual-antiplatelet the...
AIMS To evaluate the impact of an experimental strategy [23-month ticagrelor monotherapy followi...
(1) Shorter-duration dual antiplatelet therapy (DAPT) followed by single antiplatelet therapy has be...
Objectives: The aim of this study was to compare ticagrelor monotherapy with dual-antiplatelet thera...
Background: The GLOBAL LEADERS (GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platele...
Aims: To evaluate the impact of an experimental strategy [23-month ticagrelor monotherapy following ...
Aims: Optimal timing and strategy of antiplatelet monotherapy after dual-antiplatelet therapy (DAPT)...
BACKGROUND The optimal antiplatelet strategy in the second year after percutaneous coronary inter...
BACKGROUND We hypothesised that ticagrelor, in combination with aspirin for 1 month, followed by tic...
Patients undergoing staged percutaneous coronary intervention (SPCI) are exposed to extended duratio...
BACKGROUND: In TWILIGHT (Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Inter...
Background: Dual antiplatelet therapy (DAPT) with a potent P2Y12 Inhibitor coupled with aspirin for ...
Patients undergoing staged percutaneous coronary intervention (SPCI) are exposed to extended duratio...
Background: The optimal antiplatelet strategy in the second year after percutaneous coronary interve...